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Abstract
Background: Currently, there are no conclusive results on the efficacy of adefovir dipivoxil
(ADV) plus lamivudine (LAM) in LAM-resistant patients with chronic hepatitis B (CHB). The aim of
study was to evaluate the efficacy of rescue therapy with ADV plus LAM compared to ADV
monotherapy in LAM-resistant CHB patients.
Results:  We searched PUBMED, EMBASE, Web of Science, CNKI (National Knowledge
Infrastructure), VIP database, the Cochrane Central Register of Controlled Trials and the
Cochrane Database of Systematic Reviews. Six eligible trials (442 patients in total) were included
and evaluated for methodologic quality and heterogeneity. Greater virological response and lower
emergence rate of ADV-associated mutants was observed in ADV plus LAM compared to ADV
monotherapy (both P < 0.05). On the contrary, the rate of ALT normalization, HBeAg clearance
and seroconversion were all similar between ADV plus LAM and ADV (all P > 0.05). Additionally,
adding-on or switch-to ADV was both well tolerated.
Conclusion: The combination of ADV with LAM was superior in inhibiting HBV replication and
preventing drug resistance as compared to ADV alone for LAM-resistant CHB patients.
Background
Chronic infection with hepatitis B virus (HBV) represents
a global health problem, with continuing new infections
worldwide, being an important cause of liver disease,
morbidity, and mortality [1,2]. The goals of therapy in
HBV infected patients are to limit or reverse progression of
the disease through sustained suppression of HBV replica-
tion [3,4]. Effective treatment of chronic hepatitis B
(CHB) improves significantly patients' survival and
reduces the risk of development of major complica-
tions[1]. Lamivudine (LAM) is the first nucleoside analog
approved for the treatment of CHB, and it has been and is
still widely applied globally for CHB patients. But it has
the major limitation of the development of drug-resist-
ance mutants occurring at a rate of 16%~32% during the
first year of treatment and increasing by 15% with each
year of additional treatment [5,6]. Available clinic data
showed that the emergence of LAM-resistant mutations
can be associated with hepatitis flares, hepatic decompen-
sation and death [7,8].
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Adefovir dipivoxil (ADV) as an oral prodrug of an acyclic
monophosphate adenine analog, has gained popularity as
a first-line treatment modality for patients with compen-
sated hepatitis B, by virtue of its satisfactory efficacy cou-
pled with an relatively good record of safety [9-11]. Given
the complementary resistance profile of HBV with LAM
and ADV, it has been regarded as a rescue therapy for
LAM-resistant CHB patients either in monotherapy or in
combination with LAM [12,13]. The combination of ADV
with LAM also has been recommended by EASL Clinical
Practice Guidelines (CPGs) if tenofovir not yet availa-
ble[14]. As we know, combination therapy offers several
advantages over monotherapy. Combining drugs may
achieve synergistic or additive antiviral effects compared
with single drug therapy. For example, more rapid
achievement of an undetectable HBV DNA level may
increase the rates of seroconversion of hepatitis B e anti-
gen (HBeAg) or normalization rate of ALT[15]. However,
it is still debated whether the combination of ADV with
LAM could improve the biochemical, virological, or sero-
logical response rates as compared with ADV alone. Some
previous studies suggested that there were no obvious
improvement in ALT normalization, virological suppres-
sion or reduction in the development of ADV-resistant
mutations for ADV+LAM combination compared with
ADV alone [16,17]. While, some other studies have
reported that in CHB patients with LAM-resistance, the
combination of ADV with LAM is superior to ADV alone,
as it is associated with higher virological response rate and
lower viral resistance rate [18-21].
According to the new guidelines of EASL, it is necessary to
do deep into exploring various new strategies including
appropriate combination therapy to achieve optimal cur-
ative effect for CHB patients[14]. At present, there were no
evidence-based conclusive results on efficacy (including
biochemical improvement, HBV DNA suppression,
HBeAg clearance and seroconversion, and the develop-
ment of subsequent ADV resistance) of ADV plus LAM
combination therapy versus ADV monotherapy in LAM-
resistant CHB patients. In this study, we aimed to eluci-
date this topic using meta-analysis of data from published
randomized controlled trials (RCTs). The results of this
meta-analysis indicated that the therapeutic potential of
combination of ADV with LAM was beneficial for treating
LAM-resistant CHB patients, with lower incidence of
ADV-associated mutations.
Results
Characteristic and Quality of Studies
We searched relevant literatures, and finally 6 randomized
controlled trials (RCTs) were left for analysis which
involved 442 patients in total[20,22-26], of whom 213
were included in ADV+LAM combination therapy groups
and 229 were included in ADV monotherapy groups. All
included trials had clearly stated inclusion and exclusion
criteria. In addition, all studied populations with compa-
rable baseline characteristics between the combination
therapy and monotherapy groups. Of the 6 trials, 3 were
published in English[20,22,23] and the others were pub-
lished in Chinese [24-26]. The studies were of heterogene-
ous methodological quality (Jadad scores ranged from 2
to 5), and the detailed information of included RCTs was
summarized in table. 1 and table. 2.
Biochemical response
According to chi-squared statistic and I square (I2), heter-
ogeneity was assessed and not found to be a concern. Of
the six included trials, only five trials demonstrated the
biochemical response rate, and the biochemical response
rates in ADV+LAM combination group was higher as com-
pared with that in ADV monotherapy [159/208 vs. 128/
201, RR = 1.18, 95%CI (1.04-1.35), P = 0.01](Figure 1A).
However, when low-quality study was removed, the dif-
ference in response rate between two groups became sim-
ilar [99/135 vs. 77/128, RR = 1.19, 95%CI (1.00-1.42), P
= 0.05] (Figure 1B).
Virological response
According to chi-squared statistic and I square (I2), heter-
ogeneity was assessed and not found to be a concern.
Greater virological response rates were observed in
Table 1: Treatment characteristics of clinical trials included in this study
Study HBeAg status
(+/-)
Strategy for therapy Primary efficacy measures Secondary efficacy measures
Rapti (2007) - ADV 10 mg vs. ADV 10 mg + LAM 100 mg BR, VR ADV-R, AE
Chen (2008) + ADV 10 mg vs. ADV 10 mg + LAM 100 mg BR, VR, eAg-C, eAg-SC No
Yang (2008) +/- ADV 10 mg vs. ADV 10 mg + LAM 100 mg BR, VR, eAg-C, eAg-SC ADV-R, AE
Peters (2004) + ADV 10 mg vs. ADV 10 mg + LAM 100 mg BR, VR, eAg-C, eAg-SC ADV-R, AE
Xiao (2008) + ADV 10 mg (with or without an overlap 
period with LAM) vs. ADV 10 mg + LAM 
100 mg
BR, VR, eAg-C, eAg-SC No
Ijaz (2008) - ADV 10 mg vs. ADV 10 mg + LAM 100 mg VR ADV-R
ADV, adefovir dipivoxil; LAM, lamivudine; eAg-C, hepatitis B e antigen (HBeAg) clearance; eAg-SC, HBeAg seroconversion; ADV-R, ADV 
resistance; BR, biochemical response; VR, virologic response; AE, adverse event.Virology Journal 2009, 6:163 http://www.virologyj.com/content/6/1/163
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ADV+LAM combination group as compared with that in
ADV monotherapy, and the difference in response rate
between two groups were statistically significantly [134/
213 vs. 96/205, RR = 1.28, 95%CI (1.10-1.49), P =
0.002](Figure 2A). Additionally, when low-quality study
was removed, the difference in response rate was still sta-
tistically significantly [73/140 vs. 47/132, RR = 1.31,
95%CI (1.03-1.67), P = 0.03] (Figure 2B).
Hepatitis B e antigen clearance
According to chi-squared statistic and I square (I2), heter-
ogeneity was assessed and not found to be a concern. Of
the four analyzed trials, greater HBeAg clearance was
observed in combination group as compared with mono-
therapy [21/148 vs. 8/145, RR = 2.47, 95%CI (1.15-5.28),
P = 0.02](Figure 3A). However, when low-quality study
was removed, the difference in HBeAg clearance between
Table 2: Characteristics of included clinical trials in meta-analysis
Study Study design Jadad score Sample size 
(monotherapy/combination therapy)
Duration of treatment
(week)
Follow-up period
(weeks)
Rapti (2007) RCT 4 14/28 120/160 40
Chen (2008) RCT 4 34/34 48 12
Yang (2008) RCT 2 73/73 48 12
Peters (2004) RCT, DB 5 19/20 48 12
Xiao (2008) RCT 4 85/54 88 22
Ijaz (2008) RCT, 3 4/4 79/71 20/17
RCT, randomized controlled trial; DB, double blind.
Analysis of the biochemical response of ADV+LAM combination therapy versus ADV monotherpy for treatment of LAM- resistance CHB patients Figure 1
Analysis of the biochemical response of ADV+LAM combination therapy versus ADV monotherpy for treat-
ment of LAM-resistance CHB patients. A: five trials were analyzed; B: four trials were analyzed.Virology Journal 2009, 6:163 http://www.virologyj.com/content/6/1/163
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two groups became similar [14/106 vs. 7/114, RR = 2.02,
95%CI (0.89-4.57), P = 0.09] (Figure 3B).
Hepatitis B e antigen seroconversion
According to chi-squared statistic and I square (I2), heter-
ogeneity was assessed and not found to be a concern. Of
the four analyzed trials, greater HBeAg seroconversion
was observed in combination group as compared with
monotherapy [21/148 vs. 8/145, RR = 2.47, 95%CI (1.15-
5.28), P = 0.02](Figure 4A). However, when low-quality
study was removed, the difference between two groups
became similar [14/106 vs. 7/114, RR = 2.02, 95%CI
(0.89-4.57), P = 0.09](Figure 4B).
Emergence of ADV-resistant mutation
Of the six included studies, four studies detected ADV-
resistant mutants during the course of treatment. Accord-
ing to chi-squared statistic and I square (I2), heterogeneity
was assessed and not found to be a concern. Greater emer-
gence rates of ADV-resistant mutants were observed in
ADV monotherapy as compared with ADV+LAM combi-
nation therapy [0/125 vs. 6/110., RR = 0.15, 95%CI(0.03-
0.74), P = 0.02](Figure 5A). Interesting, after low-quality
study was removed, the difference in ADV-associated
mutations was still statistic significantly between two
group [14/106 vs. 7/114, RR = 2.02, 95%CI (0.89-4.57),
P = 0.09](Figure 5B).
Safety
For majority of the included trials, long-term ADV treat-
ment in LAM-resistance chronic hepatitis B patients either
alone or in combination with LAM, was general well tol-
erated. Only Rapti I et al.[22] in their study reported that
3 patients with cirrhosis in ADV+LAM combination ther-
apy developed HCC, and 2 patients with cirrhosis had a
decrease of creatinine clearance in combination therapy
group, but no statistically significant difference were seen
between combination of ADV with LAM and ADV alone.
Discussion
The prevalence of drug-resistant mutants in patients is
associated with the loss of clinical and virological bene-
Analysis of the virological response of ADV+LAM combination therapy versus ADV monotherpy for treatment of LAM-resist- ance CHB patients Figure 2
Analysis of the virological response of ADV+LAM combination therapy versus ADV monotherpy for treat-
ment of LAM-resistance CHB patients. A: six trials were analyzed; B: five trials were analyzed.Virology Journal 2009, 6:163 http://www.virologyj.com/content/6/1/163
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fits[27], and may limit future therapeutic options. So pre-
vention is important for long-term therapeutic efficacy.
The use of combination therapy is particularly important
given the limited number of treatment options available
for patients with drug-resistant HBV infection. In success-
ful antiviral therapy of patients, drug combinations can
delay or prevent the emergence of drug-resistant mutants.
However, combination therapy was recommended only
when drugs with a low barrier to resistance are used, such
as LAM and ADV. And combined drugs should have com-
plementary resistance profiles[15]. Recently, there are a
growing number of studies of ADV and LAM combination
therapy in treatment-experienced patients with LAM-
resistant HBV, and their results indicated that the combi-
nation of ADV with LAM is superior to ADV alone in
patients with LAM-resistant HBV infection[18,20,28].
However, the overall benefits of the combination of ADV
with LAM have not been fully assessed quantitatively. This
study is the first to examine the combination of ADV with
LAM for LAM-resistant patients, pooling data from related
trials into meta-analysis, and the results of this study will
aid in achieving evidence-based conclusions on the
advantages of combination therapy of ADV with LAM.
As we know, LAM-resistant and wild-type HBV likely coex-
ist as vial quasispecies in patients. Because either ADV or
LAM exert antiviral activity against wild-type HBV, and
LAM-resistant HBV are still hypersensitive to ADV, the
combination of LAM and ADV could inhibit the replica-
tion of wild-type and LAM-resistant HBV collabora-
tively[29]. In this meta-analysis, ADV administered in
combination with LAM was found to be effective, associ-
ated with greater virological responses rates and lower
drug resistant rates as compared to ADV alone in patients
with drug-resistant to LAM. Despite the limited number of
patients and relatively short duration in two groups, the
difference in virological response rate is still statistically
significant (P < 0.05). Results from currently available
studies of ADV therapy in patients with clinical resistance
to LAM suggest an inverse relationship between pretreat-
ment levels of viremia and antiviral response[6]. The
power of pretreatment viremia in predicting a response to
ADV was supported in previous studies by the significant
Analysis of the HBeAg clearance of ADV+LAM combination therapy versus ADV monotherpy for treatment of LAM-resistance  CHB patients Figure 3
Analysis of the HBeAg clearance of ADV+LAM combination therapy versus ADV monotherpy for treatment 
of LAM-resistance CHB patients. A: four trials were analyzed; B: three trials were analyzed.Virology Journal 2009, 6:163 http://www.virologyj.com/content/6/1/163
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response to ADV in LAM-naive patients with chronic HBV
infection and circulating low pretreatment levels of HBV
DNA. In this meta-analysis, there was no evidence of pre-
existing ADV-resistant variants, which may be correlated
with the significant virological response in a short
period[30], especially for patients receiving combination
of ADV with LAM. Moreover, longer duration treatment
showed superiority of combination therapy over ADV
alone in preventing ADV resistance [20], which is consist-
ent with the results of this study. For example, the results
of a retrospective-prospective study consisting of 585
patients with LAM-resistant CHB treated with combina-
tion of ADV with LAM or ADV alone for a median of 33
months suggested that the 3-year cumulative risk of ADV
resistance was 16% in the ADV alone versus 0% in the
combination of ADV with LAM (P < 0.001)[31].
It has been identified that LAM-resistance mutations
occurs as a result of mutation at position 204 or 180 of the
HBV DNA polymerase, which remain sensitive to ADV.
Resistance to ADV is prevalent due to rtA181V and
rtN236T mutations[29]. Recently, someone reported that
a single amino acid change at position rt181 may induce
cross-resistance to LAM and ADV[32], but this phenome-
non was not widely observed in clinical practice. In
another word, majority of currently available data sug-
gested that the combination of ADV with LAM could elim-
inate or hamper the emergence of ADV-resistant strains
for LAM-resistant patients. So, the possible explanation
for this low resistant rate is the ability of ADV and LAM in
combination to cross-inhibit the corresponding drug-
related HBV mutants, thereby preventing accumulation of
mutated strains with adequate fitness for replication.
However, the combination of ADV with LAM did not
completely prevent virological breakthrough or drug
resistance in all patients.
In this meta-analysis, either combination of ADV with
LAM or ADV alone was well tolerated. And the emergence
rate of adverse events was not significant to combination
as compared to ADV alone, even limited data were availa-
ble regarding renal toxicity when safety was assessed. In
Analysis of the HBeAg/anti-HBe serum seroconversion of ADV+LAM combination therapy versus ADV monotherpy for treat- ment of LAM-resistance CHB patients Figure 4
Analysis of the HBeAg/anti-HBe serum seroconversion of ADV+LAM combination therapy versus ADV mono-
therpy for treatment of LAM-resistance CHB patients. A: four trials were analyzed; B: three trials were analyzed.Virology Journal 2009, 6:163 http://www.virologyj.com/content/6/1/163
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one study of 145 patients with LAM resistance, only 8% of
patients developed mild nephrotoxicity, but all were able
to continue combination therapy after increasing the
ADV-dosing interval[33]. And in another RCT studies of
LAM versus LAM plus ADV including 115 treatment-
native patients, none of the patients receiving combina-
tion therapy developed nephrotoxicity[34].
Recently, combination of ADV with LAM was also recom-
mended as a good choice for LAM-resistant patients by the
new guidelines of American Association for the Study of
Liver Diseases (AASLD) and Asian Pacific Association for
the Study of Liver (APASL). After referring to the results of
this meta-analysis and wealth of data presented by previ-
ous retrospective and prospective trials of larger sample,
we believe that the combination of ADV with LAM would
be a good option for LAM-resistant patients.
Conclusion
The combination of ADV with LAM was superior in inhib-
iting HBV replication and preventing drug resistance as
compared to ADV alone for LAM-resistant CHB patients.
It is thus recommended that the combination therapy of
LAM plus ADV could be used as an option for patients
with LAM-resistant HBV infection.
Methods
Search strategy
We searched the following databases until February 2009:
PUBMED from 1966, EMBASE from 1966, Web of Science
from 1955, CNKI (National Knowledge Infrastructure)
from 1980, and Chinese VIP database from 1989. The
Cochrane Central Register of Controlled Trials and the
Cochrane Database of Systematic Reviews were also
searched. Of these databases, CNKI and VIP databases
provide literatures in Chinese. In this study, the search
was designed using "adefovir", "lamivudine", "lamivu-
dine failure", or "lamivudine resistance". Reference lists
from retrieved documents were also searched. To maxi-
mize data requisition, we contacted authors whose articles
contained inadequate information.
Analysis of the ADV-resistance mutation of ADV+LAM combination therapy versus ADV monotherpy for treatment of LAM- resistance CHB patients Figure 5
Analysis of the ADV-resistance mutation of ADV+LAM combination therapy versus ADV monotherpy for 
treatment of LAM-resistance CHB patients. A: four trials were analyzed; B: three trials were analyzed.Virology Journal 2009, 6:163 http://www.virologyj.com/content/6/1/163
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Inclusion and exclusion criteria
The following inclusion criteria were used: (i) study
design: randomized controlled trial, (ii) study popula-
tion: LAM-resistant CHB patients; (iii) intervention: ADV
monotherapy versus LAM and ADV combination therapy.
Our search was limited to human studies and the follow-
ing exclusion criteria were used: (i) examining the non-
adult population; (ii) not reporting any of the primary
efficacy measures as defined by the authors.
Data extraction
Two investigators independently screened titles and
abstracts, selected the trials and performed the data extrac-
tion. The conflict in data extraction was resolved by dis-
cussion among investigators and reference to the original
article. In some cases, original principal investigators were
contacted to collect information that was collected but
not published. When several publications pertaining to a
single study were identified, the most recent and complete
publication was used.
Efficacy measures and definitions
The rates of biochemical response, virological response,
and HBeAg seroconversion were used as primary efficacy
measures. Emergence of ADV associated mutation and the
safety of combination therapy were used as secondary effi-
cacy measures. Biochemical response was defined as nor-
malization of ALT levels; Virological response was defined
as attainment of undetectable levels of HBV DNA; HBeAg
clearance was defined as HBeAg disappearance and sero-
conversion was defined as HBeAg antibodies appearance.
The emergence of ADV resistance was defined as the detec-
tion of rtN236T or rtA181V mutation during the follow-
up period and the safety of treatment was assessed using
the occurrence rate of adverse events including renal dys-
function, decompensation of cirrhosis and hepatocellular
carcinoma (HCC).
Study quality
The methodological quality of included trial was assessed
using the modified Jadad quality scale, which was calcu-
lated by assessing four items: random sequence genera-
tion, allocation concealment, blind method, and
description of withdrawals and dropouts. The qualities of
the first three items were classified into three grades
respectively: adequate (2 points), unclear (1 point), and
inadequate (0 point). And the fourth item was classified
into two grades: described (1 point) and not described (0
point). The scores of modified Jadad quality scale were
ranged from 0 to 7, with scores ≥ 4 signifying high-quality
studies. Heterogeneity was assessed for each analysis.
Data analysis
Data analysis was carried out with the use of Review Man-
ager Software 4.2 (Cochrane Collaboration, Oxford,
United Kingdom). For each eligible study, dichotomous
data were presented as relative risk (RR), and continuous
outcomes were presented as weighted mean difference
(WMD), both with 95% confidence intervals (CI). Meta-
analysis was performed using fixed-effect or random-
effect methods, depending on the absence or presence of
significant heterogeneity. Statistical heterogeneity
between trials was evaluated by the chi-square and I-
square (I2) tests, with significance set at P < 0.10. In the
absence of statistically significant heterogeneity, the fixed-
effect method was used to combine the results. When het-
erogeneity was confirmed (P < 0.10), the random-effect
method was used. Additionally, sensitivity analysis
should be carried out if low quality trials were included.
The overall effect was tested using z scores, with signifi-
cance set at P < 0.05.
Competing interests
The funding source had no influence on study design, in
the collection, analysis, and interpretation of the data, in
the writing of the manuscript, or in the decision to submit
the manuscript for publication. The contents are solely the
responsibility of the authors and do not necessarily repre-
sent the views of the funding source.
Authors' contributions
TH conceived the study, provided fund supporting and
revised the manuscript critically for important intellectual
content. CEQ and WLC made substantial contributions to
its design, acquisition, analysis and interpretation of data.
LJ and XL participated in the design, acquisition, analysis
and interpretation of data. All authors contributed equally
to this manuscript. All authors read and approved the
final manuscript.
Acknowledgements
This work was financial supported by the National Basic Research Program 
of China (No.2007CB512902 and No.2006CB504302) and the National 
Key Technologies Research and Development Program of China during the 
11th Five-year Plan Period (2008ZX10002-006). We thank Prof. Tai-Xiang 
Wu (Chinese Cochrane Center and Chinese Evidence-Based Medicine 
Center, West China Hospital, Sichuan University, China) for his advice on 
this study.
References
1. Lok AS, McMahon BJ: Chronic hepatitis B: update of recom-
mendations.  Hepatology 2004, 39:857-861.
2. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee
T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrho-
sis Asian Lamivudine Multicentre Study Group: Lamivudine for
patients with chronic hepatitis B and advanced liver disease.
N Engl J Med 2004, 351:1521-1531.
3. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ,
Locarnini S, Martin P, Richman DD, Zoulim F: Virologic monitor-
ing of hepatitis B virus therapy in clinical trials and practice:
recommendations for a standardized approach.  Gastroenterol-
ogy 2008, 134:405-415.
4. Conjeevaram HS, Lok AS: Management of chronic hepatitis B.  J
Hepatol 2003, 38:S90-103.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2009, 6:163 http://www.virologyj.com/content/6/1/163
Page 9 of 9
(page number not for citation purposes)
5. Mohanty SR, Kupfer SS, Khiani V: Treatment of chronic hepatitis
B.  Nat Clin Pract Gastroenterol Hepatol 2006, 3:446-458.
6. Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogianna-
kos J, Christias E, Saveriadis A, Pavlidis C, Triantos C, Christidou A,
Papatheodoridis G, Karamanolis D, Tzourmakliotis D: Long-term
therapy with adefovir dipivoxil in hepatitis B e antigen-nega-
tive patients developing resistance to lamivudine.  Aliment
Pharmacol Ther 2008, 27:266-273.
7. Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogian-
nakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzour-
makliotis D, Avgerinos A: Clinical course of lamivudine
monotherapy in patients with decompensated cirrhosis due
to HBeAg negative chronic HBV infection.  Am J Gastroenterol
2004, 99:57-63.
8. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S,
Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ: Out-
come of hepatitis B e antigen-negative chronic hepatitis B on
long-term nucleos(t)ide analog therapy starting with lamivu-
dine.  Hepatology 2005, 42:121-129.
9. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G,
Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S,
Fry J, Brosgart CL, Adefovir Dipivoxil 438 Study Group: Adefovir
dipivoxil for the treatment of hepatitis B e antigen-negative
chronic hepatitis B.  N Engl J Med 2003, 348:800-807.
10. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jef-
fers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Ade-
fovir Dipivoxil 437 Study Group: Adefovir dipivoxil for the
treatment of hepatitis B e antigen-positive chronic hepatitis
B.  N Engl J Med 2003, 348:808-816.
11. Dando T, Plosker G: Adefovir dipivoxil: a review of its use in
chronic hepatitis B.  Drugs 2003, 63:2215-2234.
12. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo
M: Adefovir rapidly suppresses hepatitis B in HBeAg-nega-
tive patients developing genotypic resistance to lamivudine.
Hepatology 2005, 42:1414-1419.
13. Zoulim F, Parvaz P, Marcellin P, Zarski JP, Beaugrand M, Benhamou Y,
Bailly F, Maynard M, Trepo C, Trylesinski A, Monchecourt F, VIRESPA
study group: Adefovir dipivoxil is effective for the treatment of
cirrhotic patients with lamivudine failure.  Liver Int 2009,
29:420-426.
14. European Association for the Study of the Liver: EASL Clinical
Practice Guidelines:Management of chronic hepatitis B.  Jour-
nal of Hepatology 2009, 50:227-42.
15. Terrault NA: Benefits and risks of combination therapy for
hepatitis B.  Hepatology 2009, 49:S122-S128.
16. Fung J, Lai CL, Yuen JC, Wong DK, Tanaka Y, Mizokami M, Yuen MF:
Adefovir dipivoxil monotherapy and combination therapy
with lamivudine for the treatment of chronic hepatitis B in
an Asian population.  Antivir Ther 2007, 12:41-46.
17. Nam SW, Bae SH, Lee SW, Kim YS, Kang SB, Choi JY, Cho SH, Yoon
SK, Han JY, Yang JM, Lee YS: Short-term overlap lamivudine
treatment with adefovir dipivoxil in patients with lamivu-
dine-resistant chronic hepatitis B.  World J Gastroenterol 2008,
14:1781-1784.
18. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM,
Moorat A, Gardner S, Woessner M, Bourne E, et al.:  Adefovir
dipivoxil added to ongoing lamivudine in chronic hepatitis B
with YMDD mutant hepatitis B virus.  Gastroenterology 2004,
126:81-90.
19. Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, Alessan-
d r i a  C ,  Ri z ze t to  M ,  M a r za no  A :  Lamivudine-resistant chronic
hepatitis B: an observational study on adefovir in mono-
therapy or in combination with lamivudine.  J Hepatol 2008,
48:540-547.
20. Peters MG, Hann HwH, Martin P, Heathcote EJ, Buggisch P, Rubin R,
Bourliere M, Kowdley K, Trepo C, Gray DfD, et al.:  Adefovir
dipivoxil alone or in combination with lamivudine in patients
with lamivudine-resistant chronic hepatitis B.  Gastroenterology
2004, 126:91-101.
21. Kwon HC, Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo
WD: Emergence of adefovir-resistant mutants after rever-
sion to YMDD wild-type in lamivudine-resistant patients
receiving adefovir monotherapy.  J Gastroenterol Hepatol 2009,
24:49-54.
22. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ: Adding-on versus
switching-to adefovir therapy in lamivudine-resistant
HBeAg-negative chronic hepatitis B.  Hepatology 2007,
45:307-313.
23. Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS,
Naoumov NV: Dynamics of lamivudine-resistant hepatitis B
virus during adefovir monotherapy versus lamivudine plus
adefovir combination therapy.  J Med Virol 2008, 80:1160-1170.
24. Xiao Y, zheng JL, Zhang WJ, Zhou YJ, Hu CH, Hu X, Lu CH, Pan HJ:
Study of adefovir on treatment of chronic hepatitis B
patients with resistance to lamivudine: a year's clinical
course.  Chinese Hepatology 2008, 13:295-298.
25. Yang PY, Liu SH, Feng B: Effect of adefovir and lamivudine com-
bination therapy on lamivudine resistance patients.  J Fourth
Mil Med Univ 2008, 29:155-157.
26. Chen XP, Li YC, Wu SG, Chen C: Adefovir dipivoxil alone or in
combination with lamivudine in treating patients with
chronic HBeAg-positive hepatitis B resistant to the treat-
ment of lamivudine.  Journal of Guangdong Medical college 2008,
26:23-25.
27. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu
PC, Dent JC, Edmundson S, Condreay LD, Chien RN, Asia Hepatitis
Lamivudine Study Group: Extended lamivudine treatment in
patients with chronic hepatitis B enhances hepatitis B e anti-
gen seroconversion rates: results after 3 years of therapy.
Hepatology 2001, 33:1527-1532.
28. Akyildiz M, Gunsar F, Ersoz G, Karasu Z, Ilter T, Batur Y, Akarca U:
Adefovir dipivoxil alone or in combination with lamivudine
for three months in patients with lamivudine resistant com-
pensated chronic hepatitis B.  Dig Dis Sci 2007, 52:3444-3447.
29. Bartholomeusz A, Locarnini SA: Antiviral drug resistance: clini-
cal consequences and molecular aspects.  Semin Liver Dis 2006,
26:162-170.
30. Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka
T, Kobayashi M, Saitoh S, Arase Y, et al.: Low risk of adefovir
resistance in lamivudine-resistant chronic hepatitis B
patients treated with adefovir plus lamivudine combination
therapy: two-year follow-up.  J Hepatol 2008, 48:923-931.
31. Lampertico P, Marzano A, Levrero M, Santantonio T, Di Marco V,
Brunetto M, Andreone P, Sagnelli E, Fagiuoli S, Mazzella G, Raimondo
G, Gaeta GB, Ascione A, On behalf of the AISF Adefovir Study Group:
Adefovir and lamivudine combination therapy is superior to
ADV monotherapy for lamivudine-resistant patients with
HBeAG-negative chronic hepatitis B.  Digestive and Liver Disease
2007, 39:A7.
32. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C,
Zoulim F: Impact of hepatitis B virus rtA181V/T mutants on
hepatitis B treatment failure.  J Hepatol 2008, 48:747-755.
33. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo
M: Low resistance to adefovir combined with lamivudine: a 3-
year study of 145 lamivudine-resistant hepatitis B patients.
Gastroenterology 2007, 133:1445-1451.
34. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Bro-
sgart CL, Woessner MA, Scott SA, Gray DF, Gardner SD: Lamivu-
dine compared with lamivudine and adefovir dipivoxil for the
treatment of HBeAg-positive chronic hepatitis B.  J Hepatol
2008, 48:728-735.